Lumen Bioscience, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seattle WA United States (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2020
NCT04098263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Lumen Bioscience, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

spirulina (2 trials)

Drugs in Phase 2 Trials (1)

lmn-101 (2 trials)

Drugs in Phase 1 Trials (1)

lmn-301 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Campylobacter Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3